Evolution of intratumoral genetic heterogeneity during colorectal cancer progression.

Evolution of intratumoral genetic heterogeneity during colorectal tumor progression has not been investigated so far. Multiple sample areas in colorectal adenocarcinoma at early and advanced stages and in metastases were studied for the well-known genetic alterations: K-ras and p53 point mutations and loss of heterozygosity (LOH) on chromosomes 5q and 18q. In primary colorectal cancers (CRCs), intratumoral genetic heterogeneity was more often observed in early than in advanced stages, at 90 and 67%, respectively. All but one of the advanced CRCs were composed of one predominant clone and other minor clones, whereas no predominant clone has been identified in half of the early cancers. At the early stage, the last events that were produced, the p53 mutation and LOH of 18q, were also the most heterogeneous. At the advanced stage, the LOH of 5q and 18q were the most frequent heterogeneous events (67 and 58%, respectively). The intratumoral heterogeneity for mutations was significantly reduced, from the early to the advanced stages (from 60 to 20% for K-ras and from 70 to 20% for p53). On the other hand, a quasi absence of intratumoral genetic heterogeneity was observed for K-ras and p53 in distant metastasis. In conclusion, colorectal adenocarcinomas are characterized by marked intratumoral genetic heterogeneity. A reduction of the intratumoral genetic heterogeneity for point mutations and a relative stability of the heterogeneity for allelic losses indicate that, during the progression of CRC, clonal selection and chromosome instability continue, while an increase cannot be proven.

[1]  M. Hawn,et al.  Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. , 1998, Gastroenterology.

[2]  福成 博幸 Intratumoral heterogeneity of genetic changes in primary colorectal carcinomas with metastasis , 2004 .

[3]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[4]  W. Giaretti,et al.  Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. , 1996, The American journal of pathology.

[5]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[6]  Martin A. Nowak,et al.  The significance of unstable chromosomes in colorectal cancer , 2003, Nature Reviews Cancer.

[7]  N. Konishi,et al.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. , 1995, The American journal of pathology.

[8]  S. Cascinu,et al.  Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Bapat,et al.  Genomic instability and cancer. , 2003, Current molecular medicine.

[10]  J. Benhattar,et al.  Microdissection by exclusion and DNA extraction for multiple PCR analyses from archival tissue sections. , 2000, BioTechniques.

[11]  T. Owonikoko,et al.  Intratumoral genetic heterogeneity in Barrett adenocarcinoma. , 2002, American journal of clinical pathology.

[12]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[13]  R. Orecchia,et al.  Intratumor heterogeneity of chromosome 1, 7, 17, and 18 aneusomies obtained by FISH and association with flow cytometric DNA index in human colorectal adenocarcinomas. , 1999, Cytometry.

[14]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[15]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[16]  B. Iacopetta,et al.  The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival , 1994, International journal of cancer.

[17]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[18]  A. Jauch,et al.  Intratumoral genomic heterogeneity in advanced head and neck cancer detected by comparative genomic hybridization. , 2005, Advances in Oto-Rhino-Laryngology.

[19]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[20]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[21]  G. Thomas,et al.  Association of p53 mutations with short survival in colorectal cancer. , 1994, Gastroenterology.

[22]  J W Arends,et al.  Molecular interactions in the Vogelstein model of colorectal carcinoma , 2000, The Journal of pathology.

[23]  N. Carter,et al.  Array Comparative Genomic Hybridization Analysis of Colorectal Cancer Cell Lines and Primary Carcinomas , 2004, Cancer Research.

[24]  Kathleen R. Cho,et al.  Identification of a chromosome 18q gene that is altered in colorectal cancers. , 1990, Science.

[25]  B. Iacopetta,et al.  Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. , 2000, European journal of cancer.

[26]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.

[27]  C. Langner,et al.  Pitfalls in diagnostic molecular pathology – significance of sampling error , 2001, Virchows Archiv.

[28]  M. Duffy,et al.  Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. , 2003, European journal of cancer.